Equities

Biostem Technologies Inc

BSEM:PKC

Biostem Technologies Inc

Actions
Consumer DiscretionaryConsumer Discretionary
  • Price (USD)22.80
  • Today's Change2.47 / 12.13%
  • Shares traded96.94k
  • 1 Year change+667.68%
  • Beta1.5540
Data delayed at least 15 minutes, as of Nov 08 2024 20:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioStem Technologies, Inc. is focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. Its products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. AmnioWrap is a placental-based allografts comprised of unseparated amnion and chorion membranes, including the intact intermediate layer.

  • Revenue in USD (TTM)131.44m
  • Net income in USD7.87m
  • Incorporated2009
  • Employees67.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eton Pharmaceuticals Inc31.38m-6.69m226.84m30.00--16.79--7.23-0.2596-0.25961.220.52291.008.827.891,046,033.00-21.31-46.22-38.27-58.2059.4872.16-21.31-76.861.28--0.2571--48.90--89.62--26.85--
Inhibrx Biosciences Inc1.85m1.63bn234.65m166.000.13371.070.1434126.63121.21121.210.043415.150.0079--4.8611,162.65693.63-77.06815.31-93.91----88,264.55-1,590.91---21.960.00---17.88-26.85-66.20--26.30--
Lifecore Biomedical Inc128.45m5.71m248.21m524.00182.46--17.241.930.03690.05953.821.280.52172.014.96245,124.002.32-5.912.74-8.3334.6531.014.45-19.160.8030.1250.7641--24.20-25.46114.5334.47-16.72--
Precigen Inc4.39m-135.38m278.63m202.00--5.71--63.48-0.5407-0.54070.01760.17090.0313--4.7121,727.72-96.46-31.50-119.34-38.63-13.5644.00-3,084.55-232.32----0.00---76.87-47.16-20.22---48.30--
Sanara Medtech Inc72.41m-6.57m308.24m107.00--7.39--4.26-0.7788-0.77888.624.771.101.868.13676,731.00-10.16-17.73-12.08-22.0789.7388.08-9.23-17.131.49-4.880.2577--41.7761.9345.79--99.09--
Biostem Technologies Inc131.44m7.87m371.35m67.0068.1420.5145.942.830.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Revance Therapeutics Inc247.00m-180.81m385.47m597.00------1.56-1.91-1.952.55-1.550.4971.036.71413,740.40-36.38-55.55-43.47-63.2072.61---73.20-304.963.05-15.401.58--76.55128.849.10---0.3022--
Rigel Pharmaceuticals Inc130.30m-14.23m388.32m147.00------2.98-0.8136-0.81367.45-1.701.061.055.24886,401.40-11.59-28.82-19.93-47.2692.4197.88-10.92-35.761.48-1.732.00---2.7921.3057.16--68.45--
Theravance Biopharma Inc62.02m-45.65m437.36m99.00--2.26--7.05-0.924-0.9241.253.960.1534--4.12626,434.30-11.29-40.51-12.00-48.50-----73.61-305.27----0.1305--11.84-0.995640.54---19.24--
Esperion Therapeutics Inc295.45m-86.77m447.39m240.00------1.51-0.6585-0.65851.72-1.891.100.82755.351,231,046.00-32.41-69.45-74.85-101.8181.58---29.37-147.441.370.3253----54.14--10.45------
Amylyx Pharmaceuticals Inc298.76m-165.87m456.15m384.00--1.75--1.53-2.45-2.454.343.840.76053.6915.91778,026.10-42.22---50.91--84.64---55.52--4.66--0.00--1,612.94--124.84------
Zevra Therapeutics Inc23.99m-65.75m473.56m65.00--11.64--19.74-1.67-1.670.61060.77340.1919--2.09369,015.40-52.61-32.11-65.34-39.8971.78---274.10-128.42---112.940.6423--170.26---72.00--69.75--
Aquestive Therapeutics Inc58.36m-25.72m497.83m135.00------8.53-0.3565-0.35650.7874-0.38960.66852.857.25432,296.30-29.46-76.63-42.14-123.8568.4964.24-44.07-102.956.98-2.67----6.09-5.5985.54---11.42--
Xeris Biopharma Holdings Inc181.41m-59.56m517.03m377.00------2.85-0.4215-0.42151.28-0.12950.54930.74284.99481,201.60-18.04-43.60-23.57-56.5783.7278.23-32.83-143.081.69-1.591.09--48.68131.5034.23--8.43--
SNDL Inc655.68m-81.17m525.69m2.52k--0.5927--0.8018-0.3107-0.31072.503.340.59884.6333.15260,604.80-7.67-24.44-8.32-27.9425.0422.49-12.82-62.172.98--0.1125--27.63--49.83------
Data as of Nov 08 2024. Currency figures normalised to Biostem Technologies Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.